26892-90-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxyquinoline-3-carboxylic acid ethyl ester is used as a building block for the synthesis of various drugs and pharmaceuticals. Its unique chemical structure and properties make it a valuable component in the development of new medications.
Used in Antimicrobial Applications:
4-Hydroxyquinoline-3-carboxylic acid ethyl ester is used as an antibacterial and antifungal agent due to its antimicrobial properties. It has the potential to be developed into effective treatments for bacterial and fungal infections.
Used in Anti-inflammatory Applications:
4-Hydroxyquinoline-3-carboxylic acid ethyl ester is being studied for its potential anti-inflammatory properties. If proven effective, it could be used in the development of medications to treat various inflammatory conditions.
Used in Antioxidant Applications:
4-Hydroxyquinoline-3-carboxylic acid ethyl ester is also being investigated for its potential antioxidant properties. If found to be effective, it could be utilized in the development of antioxidants to combat oxidative stress and related diseases.
Used in Material Science:
4-Hydroxyquinoline-3-carboxylic acid ethyl ester's versatile chemical properties also make it a candidate for applications in material science. Its unique structure and properties could be harnessed to develop new materials with specific characteristics for various industries.

InChI:InChI=1/C12H11NO3/c1-2-16-12(15)9-7-13-10-6-4-3-5-8(10)11(9)14/h3-7H,2H2,1H3,(H,13,14)

Upstream product

• 34785-11-0 4-hydroxy-3-quinoline carboxylic acid 
• 54535-22-7 diethyl (anilinomethylene)malonate 
• 62-53-3 aniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 13720-94-0 ethyl 4-chloroquinoline-3-carboxylate 
• 64-19-7 acetic acid 
• 72368-50-4 ethyl 2-(formylamino) benzoate 
• 40516-46-9 diethyl (ethoxymethylene)malonate 
• 52119-39-8 ethyl (2-nitrobenzoyl)acetate 
• 552-16-9 ortho-nitrobenzoic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 497-19-8 sodium carbonate 
• 408508-16-7 (2-formylamino-phenyl)-propiolic acid ethyl ester 
• 116659-85-9 ethyl 3-(2-aminophenyl)-2-propynoate 

Downstream Products

• 18471-99-3 1,4-dihydro-1-methyl-4-oxoquinoline-3-carboxylic acid 
• 34785-11-0 4-hydroxy-3-quinoline carboxylic acid 
• 13720-94-0 ethyl 4-chloroquinoline-3-carboxylate 
• 611-35-8 4-chloroquinoline 
• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 873050-34-1 N-(5-amino-2-propoxyphenyl)-4-oxo-1H-quinoline-3-carboxamide 
• 857208-58-3 4-oxo-1,4-dihydroquinoline-3-carboxylic acid phenylamide 
• 873051-10-6 N-(5-amino-2-methylphenyl)-4-oxo-1H-quinoline-3-carboxamide 
• 1246213-45-5 2,4-di-tert-butyl-5-(4-oxo-1,4-dihydroquinoline-3-carboxamido)phenyl methyl carbonate 
• 873054-44-5 ivacaftor 
• 611-36-9 quinolin-4-ol 
• 116289-25-9 4-((2-hydroxyethyl)amino)quinoline 
• 1413431-07-8 N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d₃)propan-2-yl-1,1,1,3,3,3-d₆)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant academic research and scientific papers

Syntheses and photochromic behavior of biquinolinium salts

Three isomers of N,N′-dibenzy-biquinolinium dibromide were synthesized and their photoinduced coloration properties were investigated in the thin poly(N-vinylpyrrolidone) films. Upon photo-irradiation, the colorless film of 4,4′-biquinolinium salt became

PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF

Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the deriva

Synthesis method and device of 4 -hydroxyquinoline -3 - formic acid

The invention relates to the technical field of medicine preparation, and particularly discloses a synthesis method and device of 4 -hydroxyquinoline -3 - formic acid, wherein o-nitrobenzoic acid and a monoethyl propionate potassium salt are condensed to obtain 3 - (2 - nitrophenyl) -3 - oxopropanoate. The ethyl powder is reacted with 3 - (2 - nitrophenyl) -3 - oxopropanoate to obtain 3 - (2 - aminophenyl) -3 - oxopropanoate. 3 - (2 - Aminophenyl) -3 - oxopropanoate was reacted with DMF-DMA and DMF via a closed loop to give 4 -hydroxyquinoline -3 - ethyl ester. The 4 -hydroxyquinoline -3 - formate was hydrolyzed under basic conditions to give 4 -hydroxyquinoline -3 - formic acid. 4 -hydroxyquinoline -3 - formic acid has the advantages of low cost, short reaction time and simple post-treatment in the synthesis process.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

Combining 1,3-Ditriazolylbenzene and Quinoline to Discover a New G-Quadruplex-Interactive Small Molecule Active against Cancer Stem-Like Cells

Quadruplex nucleic acids are promising targets for cancer therapy. In this study we used a fragment-based approach to create new flexible G-quadruplex (G4) DNA-interactive small molecules with good calculated oral drug-like properties, based on quinoline

COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS

Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Methods of treating cystic fibrosis comprising administering at least Compound (I) of the formula. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound (I).

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

COMPOSITIONS FOR TREATING CYSTIC FIBROSIS

A single tablet comprising Compound I:. Methods of treating cystic fibrosis comprising administering one or more of such single tablets to a patient.